Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). A team from Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor (CAR) T cells enhanced with the protein interleukin-15 (IL-15). The findings are published in Nature.
This article was originally published on MedicalXpress.com
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
© 2024 SimplyWell.ca